Teva believes that it can file [thrice-weekly NDA] on the one year data.
That’s what Teva is telling investors, but it makes a lot of sense, IMO, for the FDA to want to see some safety data from the open-label extension insofar as the dose per administration is double the normal amount.
Moreover, Teva does not exactly have a history of playing straight with its regulatory disclosures to investors; Lovenox is a case in point.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.